surrounding the key issues to occur, such as any
difference between valuing technologies in the Latin
America Region with the approaches made in the
European Union and North America.

OP11 Findings From The 2017
Health Technology Assessment
International Asia Policy Forum
Survey

AUTHORS:
Linda Mundy, Rebecca Trowman (rtrowman@htai.org),
Brendon Kearney

INTRODUCTION:
Health systems in the Asia region seek to achieve
universal health care (UHC) by increasing access to
essential healthcare services, while reducing health
inequalities and out-of-pocket expenditure. With this in
mind, the discussion for the 2017 Health Technology
Assessment International (HTAi) Asia Policy Forum (APF)
centered around the topic of ‘Universal Healthcare in
the Asia Region: Overcoming the Barriers using HTA and
Real World Data’.

METHODS:
As part of the background paper prepared to inform
discussions at the APF, attendees from public sector
HTA agencies from nine countries, and industry
attendees from eight companies, were surveyed to
explore issues on the barriers and challenges of
establishing UHC in the region and use of real world
data (RWD).

RESULTS:
Most countries used evidence-based decision-making
when considering which technologies to add to
healthcare benefit packages; however, this was at times
inconsistently applied. Prioritization criteria included
burden of disease, unmet clinical need, clinical
effectiveness, cost effectiveness and affordability. The
political agenda and deference to expert opinion also
played a role. Although all countries reported using
RWD to inform decision-making, they also reported
issues including lack of capacity, poor quality data and
lack of collaboration between private and public
sectors, as well as a conservative approach to data-
linkage. It became apparent that a disconnect had been
identified, as industry overwhelmingly identified access
to RWD in the region as a major issue.

CONCLUSIONS:
Discussing the differences in opinion between HTA
agencies and industry led to a greater understanding of
issues in the Asia region, and will lead to increased
dialogue and opportunities to collaborate in the future.
Building capacity in the region will assist countries to
deliver on their goal of achieving UHC.

OP12 2017 Health Technology
Assessment International Asia
Policy Forum: The Importance Of
Universal Health Care

AUTHORS:
Andrew Rintoul, Rebecca Trowman
(rtrowman@htai.org)

INTRODUCTION:
The fifth Health Technology Assessment International
(HTAi) Asia Policy Forum (APF) was held in Beijing,
November 2017. The topic of the meeting was
‘Universal Health Care in the Asia Region: Overcoming
the Barriers using HTA and Real World Data’. This
presentation will focus on the goal of achieving
universal health care (UHC) in the Asia region, and
specifically the perspective of the World Health
Organization (WHO).

METHODS:
The 2017 HTAi APF had senior representatives from HTA
agencies, academia, industry active in the region plus
representatives from the WHO Geneva office and the
Western Pacific Regional Office. A keynote presentation
was delivered by the WHO representative and there
were guided breakout group discussions.

RESULTS:
UHC is a key component of the overall aims and
objectives of the WHO; universal access to safe,
effective, quality and affordable medicines and vaccines
for all is at the heart of this. Pharmaceutical spending
varies widely across the Asia region and all countries in
the region share common problems in attaining UHC.
These include inadequate financing, inefficiencies in

https://doi.org/10.1017/S0266462318000776 Published online by Cambridge University Press
procurement and supply chain management, limited use of effective pricing policies and negotiations, substandard quality of medicines and widespread inappropriate prescribing and use.

**CONCLUSIONS:**

HTA can be used to help countries in the Asia region to achieve UHC; it is a tool to support good decision making and hence can help promote more efficient allocation of limited resources. Affordability, however, needs to be at the center of any decision to invest or disinvest, and incremental cost effectiveness ratios should not be used as the sole basis for decision making.

---

**OP13 2017 Health Technology Assessment International Asia Policy Forum: The Perspective Of Not-For-Profit Members**

**AUTHORS:**

Raoh-Fang Pwu, Rebecca Trowman (rtrowman@htai.org)

**INTRODUCTION:**

The fifth Health Technology Assessment International (HTAi) Asia Policy Forum (APF) was held in Beijing, November 2017. The topic of the meeting was ‘Universal Health Care in the Asia Region: Overcoming the Barriers using HTA and Real World Data’. This presentation will focus on the use of real world data (RWD) as a mechanism of informing HTA in the Asia region – from the perspective of the not-for-profit HTA agencies that were represented at the APF.

**METHODS:**

The 2017 HTAi APF had senior representatives from government and HTA agencies from 11 countries in the Asia region. This included first-time attendees from Iran, Indonesia and the Philippines. A keynote presentation on the lessons learnt from Taiwan on the use of RWD was delivered, and there were guided breakout group discussions.

**RESULTS:**

There are a number of registries and sources of RWD available to the HTA agencies across the Asia region. However it was noted that the databases are resource intensive to maintain, and there are noted time lags in the data collection and release. There are examples where the data from these sources have been used to evaluate local utilization of treatments and post-market surveillance, but it has not yet been used in pricing/reimbursement decisions.

**CONCLUSIONS:**

Although RWD could be a good tool for healthcare decision-making in the Asia region, it is still unclear how to do so properly. Infrastructure and human capacity, as well as law, are key factors to the successful use of RWD. Standardized methodologies, increased transparency, quality control and capacity building are essential elements to better implementing RWD in HTA.

---

**OP14 The 2017 Health Technology Assessment International Asia Policy Forum: The Perspective Of Industry Members**

**AUTHORS:**

Parashar Patel, Rebecca Trowman (rtrowman@htai.org)

**INTRODUCTION:**

The fifth Health Technology Assessment International (HTAi) Asia Policy Forum (APF) was held in Beijing, November 2017. The topic of the meeting was ‘Universal Health Care in the Asia Region: Overcoming the Barriers using HTA and Real World Data’. This presentation will focus on the use of real world data (RWD) as a mechanism of informing HTA in the Asia region – from the perspective of industry that were represented at the APF.

**METHODS:**

The 2017 HTAi APF had senior representatives from 11 pharmaceutical and medical device companies active in the region. A keynote presentation was delivered that explored the findings of the background paper and survey, and there were guided breakout group discussions.

**RESULTS:**

RWD is needed in all stages of the life cycle of a product; however, of greatest importance to industry is RWD to